A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Advanced Search

You could also try: not including (1000), without (1000)

Pembrolizumab 200mg (NSCLC)

Description
Regimen Chemotherapy Protocol LUNG CANCER Pembrolizumab (200mg) • Lung Cancer – Pembrolizumab (200mg) Indication The treatment of untreated PD-L1 positive metastatic non
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Pembrolizumab-200mg.pdf

Pembrolizumab 400mg (bladder)

Description
Chemotherapy Protocol BLADDER CANCER Pembrolizumab (400mg) Regimen • Bladder – Pembrolizumab (400mg) Indication • Pembrolizumab is indicated for locally advanced (ie T4b any N
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Bladdercancer/Pembrolizumab-400mg.pdf

Pembrolizumab 200mg (bladder)

Description
Chemotherapy Protocol BLADDER CANCER Pembrolizumab (200mg) Regimen • Bladder – Pembrolizumab (200mg) Indication • Pembrolizumab is indicated for locally advanced (ie T4b any N
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Bladdercancer/Pembrolizumab-200mg.pdf

Nivolumab 480mg (renal)

Description
Chemotherapy Protocol RENAL CELL CANCER Nivolumab (480mg-28 days) Regimen • Renal Cell – Nivolumab (480mg-28 days) Indication • Nivolumab is recommended, within
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Renal-cell/Nivolumab-480mg.pdf

Nivolumab 240mg (renal)

Description
Chemotherapy Protocol RENAL CELL CANCER Nivolumab (240mg-14 days) Regimen • Renal Cell – Nivolumab (240mg-14 days) Indication • Nivolumab is recommended, within
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Renal-cell/Nivolumab-240mg.pdf

RGDP-Cisplatin-Dexamethasone-Gemcitabine-Rituximab

Description
Chemotherapy Protocol LYMPHOMA CISPLATIN-DEXAMETHASONE-GEMCITABINE-RITUXIMAB (RGDP) Regimen • Lymphoma – RGDP-Cisplatin-Dexamethasone-Gemcitabine-Rituximab Indication • Patients with relapsed aggressive B
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/RGDP-Cisplatin-Dexamethasone-Gemcitabine-Rituximab.pdf

RFC PO (Lite) - Cyclophosphamide-Fludarabine- Rituximab PO (Lite) Ver 1.2

Description
Chemotherapy Protocol LYMPHOMA CYCLOPHOSPHAMIDE–FLUDARABINE–RITUXIMAB (RFC Oral Lite) Regimen Lymphoma – RFC PO (Lite) - Cyclophosphamide-Fludarabine-Rituximab PO (Lite) Indication CD20
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/RFC-PO-Lite-Cyclophosphamide-Fludarabine-Rituximab-PO-Lite-Ver-1.2.pdf

RCVP-Cyclophosphamide-Prednisolone-Rituximab-Vincristine Ver 1.2

Description
Chemotherapy Protocol LYMPHOMA CYCLOPHOSPHAMIDE-PREDNISOLONE-RITUXIMAB-VINCRISTINE (RCVP) Regimen Lymphoma – RCVP-Cyclophosphamide-Prednisolone-Rituximab-Vincristine Indication Non-Hodgkin’s Lymphoma Toxicity
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/RCVP-Cyclophosphamide-Prednisolone-Rituximab-Vincristine-Ver-1.2.pdf

RCHOP(21)-Cyclophosphamide-Doxorubicin-Prednisolone-Rituximab-Vincristine (21) Ver 1.2

Description
Chemotherapy Protocol LYMPHOMA CYCLOPHOSPHAMIDE-DOXORUBICIN-PREDNISOLONE-RITUXIMAB-VINCRISTINE (21) (RCHOP 21) There are multiple versions of this protocol in use. Please
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/RCHOP21-Cyclophosphamide-Doxorubicin-Prednisolone-Rituximab-Vincristine-21-Ver-1.2.pdf

RCHOP(14)-Cyclophosphamide-Doxorubicin-Prednisolone-Rituximab-Vincristine (14) Ver 1.2

Description
Chemotherapy Protocol LYMPHOMA CYCLOPHOSPHAMIDE-DOXORUBICIN-PREDNISOLONE-RITUXIMAB-VINCRISTINE- (14) (RCHOP 14) There are multiple versions of this protocol in use. Please
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/RCHOP14-Cyclophosphamide-Doxorubicin-Prednisolone-Rituximab-Vincristine-14-Ver-1.2.pdf
161 to 170 of 249
Previous … 15 16 17 18 19 … Next